Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda + chemotherapy
pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients with metastatic or locally advanced esophageal or gastroesophageal junction carcinoma who cannot undergo resection or definitive chemoradiation. The labeled junction tumors have an epicenter 1 to 5 centimeters above the junction.
LAMPGEN ANALYSIS
Why it matters
This adds a checkpoint inhibitor to chemotherapy in patients unsuitable for curative local treatment.
What research teams should watch
Capture the tumor epicenter and rationale for foregoing definitive local therapy.
PRIMARY RECORDS